When and how to treat acute hepatitis C?

Anna Licata, Antonio Craxi, Calogero Camma', Lillian Shahied, Filippo Schepis, Calogero Cammà

Risultato della ricerca: Article

92 Citazioni (Scopus)


Background: Appropriate treatment of acute hepatitis C is still a matter of controversy due to the lack of large controlled trials. Aim: To assess the effectiveness of interferon as treatment for acute hepatitis C by meta-analysis. Methods: MEDLINE search (1985-2002) was supplemented with manual searches of reference lists. Studies were included if they were controlled trials comparing interferon to no treatment and if they included patients with either post-transfusion or sporadic acute hepatitis C. Twelve trials were analyzed (414 patients). The outcome assessed was the sustained virological response (SVR) rate (undetectable hepatitis C virus RNA in serum at least 6 months after cessation of therapy). Results: Interferon significantly increased the SVR (risk difference 49%; 95% confidence interval 32.9-65%) in comparison to no treatment. The risk difference of SVR increased from 5 to 90% when trials were ordered by increasing interferon weekly dose. Delaying therapy by 8-12 weeks after the onset of disease does not compromise the SVR rate. Conclusions: Current evidence is sufficient to recommend interferon treatment of patients with acute hepatitis C. A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during the 1st month is the best option of treatment. © 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Lingua originaleEnglish
pagine (da-a)1056-1062
Numero di pagine7
RivistaJournal of Hepatology
Stato di pubblicazionePublished - 2003


All Science Journal Classification (ASJC) codes

  • Hepatology

Cita questo

Licata, A., Craxi, A., Camma', C., Shahied, L., Schepis, F., & Cammà, C. (2003). When and how to treat acute hepatitis C? Journal of Hepatology, 39, 1056-1062.